#### NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility?

Presenter: Maria Villarroel, MA

Authors: Maria A. Villarroel, MA<sup>1</sup>, Susan M. Rogers, PHD<sup>1</sup>, and William C. Miller, MD; PhD, MPH<sup>2</sup>

 Statistics and Epidemiology, RTI International
 Dept. of Medicine; Dept of Epidemiology, School of Public Health, University of North Carolina

# *C. trachomatis* (Ct) infections present a significant public health risk

Among most prevalent of all STIs
Bacterial STI; Abx Rx
Most common among young adults
Many Ct infections are asymptomatic
Untreated infection associated with significant morbidity

### Nucleic acid amplification tests (NAAT)

- Provide powerful tools for evaluating the epidemiology of Ct
- Can be used with urine, self-administered vaginal swab specimens
- Enhanced sensitivity (>90%) in comparison to traditional assays, e.g. culture
- Ability to test asymptomatic patients

#### National surveys using NAAT

- National Longitudinal Study of Adolescent Health (Miller et al., 2005)
  - 4.7% U.S. females, 3.7% males aged 18-26 Ct+
  - 14% African American females, 11.1% AA males
  - Majority asymptomatic

National Survey of Adolescent Males (Ku et al., 2002)

- 3.1% U.S. males aged 18-19, 4.5% aged 20-26 Ct+

#### **Regional studies using NAAT**

1997-98 Baltimore STD and Behavior Survey (Turner et al., 2002) (Probability sample of household population)

- 3% untreated infection (overall)
- -8% ages 18-20
- 6.4% African American;
- >90% asymptomatic
- Other Findings:
  - Few reports of recent STI risk behaviors among NAAT+
  - Untreated infections exceeded no. of treated infections reported to Health Department

#### **NAAT-identified** Ct infections

Are they clinically relevant?
Are these infections transmissible?
What is their public health significance?

#### Ct Transmissibility Study

Evaluate whether the probabilities of infection transmission, as estimated by concordance of infection between partners, are equivalent for Ct infections that are detectable only by NAAT (N+) versus infections that are detectable by traditional assay (T+)

*Hypothesis:* N+/T- are associated with *less* concordance than N+T+

#### Study design

### Screening and Index Subject Recruitment – JHH ED, Nov 2002-Feb 2005

- 18-35, sexually active
- Interview (ACASI)
- NAAT for Ct (urine, vaginal swab)

### NAAT-positives identified, recruited for follow-up

- Trained DIS (disease intervention specialists)
- Referral to General Clinical Research Center (GCRC), JHH

#### Study design (cont)

Index Follow-up Visit

 clinical exam and treatment
 Interview (ACASI) on risk behaviors
 NAATs: Urine/swab, clinician collected swab
 Traditional assay: Culture/DFA for Ct

Partner recruitment
 – Same as above

#### Results: Index subject recruitment

14,188 ED patients approached to determine eligibility

#### 6,952 eligible

 – 6,094 (88%) consented to participate, provided a specimen for NAAT

#### **Results: ED Screening for Ct**



Copyright 2007, Maria A. Villarroel, mvillarr@hotmail.com

#### Index follow-up and evaluation

419 Ct+ subjects
 - 81 (19%) Abx treatment
 - 338 Ct+ eligible for follow-up

# 166 (49%) enrolled Enrolled subjects younger, female Median time to follow-up: 21 days

# Persistence of NAAT-identified infections at follow-up



Copyright 2007, Maria A. Villarroel, mvillarr@hotmail.com

## Persistence of NAAT-identified infections

Negative NAAT at follow-up associated with:

- Female (RR=3.6, 95% CI 1.3, 9.9)

Antibiotic use in 3 months prior to ED screening (RR=2.6, 95% CI 1.2, 5.5)

#### Partner Evaluation

**175** partners identified

**152** contacted by disease intervention specialists

50 partners not enrolled

102 partners of CT+ index subjects enrolled

19 partnerships excluded

83 partnerships with NAAT and traditional assays results

#### Evidence of Ct transmission

Transmission defined by concordance within partnerships

Concordance definition: Positive NAAT (N+) or traditional assay (T+) for *C. trachomatis* among partners of Ct(+) index subjects

Ct concordance within partnerships			
	Partner		
Index	Concordant	Non-concord.	
N+T+	39 (75%)	13 (25%)	52
N+T-	14 (45%)	17 (55%)	31
	53 (64%)	30 (36%)	
Prevalence ratio= 1.7 95% CI 1.1, 2.5			

# Infection concordance within partnerships

Associated with timing of partner visit

 Persistent infections positively associated with partner concordance
 70% of partners of Ct+ index at follow-up vs.
 11% of partners of Ct- index at follow-up

### What is the meaning of a NAAT positive/culture negative Ct infection?

#### 'True' infection

Low organism burden from enhanced NAAT sensitivity

- Infection clearance
  - Lack of persistence among women
  - Non-persistent NAAT and reduced partner concordance

Residual DNA from controlled or treated infection
 Non-persistent NAAT and antibiotic use

Measurement error
 Sampling variation

False positive result?

#### Summary

- NAAT-only infections are less transmissible, as measured by partner concordance
- 45% NAAT-only infections detected in partners
- 21% of NAAT-positive had no evidence of infection at follow-up (median=21 days)

#### Other considerations

 Cannot determine direction of infection transmission
 Recruitment of partnerships difficult and

Recruitment of partnerships difficult and costly

### Support for this research was provided by NIH grant R01-HD039633 to S Rogers

Susan M. Rogers<sup>1</sup>, William C. Miller<sup>2</sup>, Charles F. Turner<sup>1,4</sup>, Jonathan Ellen<sup>3</sup>, Jonathan Zenilman<sup>3</sup>, Richard Rothman<sup>3</sup>, Maria Villarroel<sup>1</sup>, Alia Al-Tayyib<sup>2</sup>, Peter Leone<sup>2</sup>, Charlotte Gaydos<sup>3</sup>, Laxminaraya Ganapathi<sup>1</sup>, Marcia Hobbs<sup>2</sup>, David kanouse<sup>5</sup>

<sup>1</sup> RTI International

- <sup>2</sup> University of North Carolina, Chapel Hill
- <sup>3</sup> Johns Hopkins University
- <sup>4</sup> CUNY/Queens College

<sup>5</sup> RAND

#### Acknowledgements

Many thanks to the interviewing, clinical, research, DIS, and laboratory staff; the Johns Hopkins Hospital Emergency Dept, General Clinical Research Center, and International Chlamydia Center; the University of North Carolina Microbiology Lab, and RTI International.